347 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Active, not recruiting ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin s Lymphoma
Conditions: Ovarian;   Primary Peritoneal;   Serous Carcinoma;   Triple-Negative Breast;   Fallopian Tube
Intervention: Drug: ABT-888 + Cyclophospharmide
2 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
3 Active, not recruiting A Study to Compare Subcutaneous Versus Intravenous Administration of Herceptin (Trastuzumab) in Women With HER2-Positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: 5-fluorouracil;   Drug: epirubicin;   Drug: cyclophosphamide
4 Active, not recruiting ALL-SCT BFM International- HSCT in Children and Adolescents With ALL
Condition: Lymphoblastic Leukemia, Acute, Childhood;
Interventions: Drug: VP16;   Radiation: TBI;   Drug: VP16, ATG;   Drug: Fludarabine, OKT3, Treosulfan, Thiotepa
5 Recruiting Scleroderma Treatment With Autologous Transplant (STAT) Study
Condition: Systemic Scleroderma
Interventions: Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Other: questionnaire administration;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: mycophenolate mofetil;   Drug: plerixafor
6 Active, not recruiting Rituximab and Combination Chemotherapy Followed By Thalidomide in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Leucovorin;   Drug: Methotrexate;   Drug: Thalidomide;   Drug: Vincristine;   Drug: Mesna;   Drug: Filgrastim (G-CSF);   Drug: Granisetron;   Drug: Decadron
7 Withdrawn Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: Arsenic trioxide;   Drug: Bortezomib;   Drug: Melphalan;   Biological: Autologous hematopoietic stem cell transplantation
8 Recruiting A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Condition: Hematological Malignancies
Interventions: Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Thiotepa;   Genetic: Hematopoietic stem cell transplantation
9 Active, not recruiting Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Conditions: Brain Tumors;   Central Nervous System Tumors
Interventions: Drug: lomustine;   Drug: temozolomide;   Procedure: adjuvant therapy;   Radiation: radiation therapy
10 Completed
Has Results
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: O6-benzylguanine;   Drug: temozolomide
11 Completed
Has Results
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
Condition: Metastatic Malignant Melanoma
Interventions: Biological: IMC-1121B (ramucirumab);   Drug: Dacarbazine
12 Active, not recruiting Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: selumetinib;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
13 Recruiting Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Pomalidomide;   Drug: Dexamethasone
14 Active, not recruiting A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera];   Drug: Fludarabine;   Drug: Cyclophosphamide
15 Active, not recruiting A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Condition: Cancer
Intervention: Drug: Sativex
16 Recruiting Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide;   Drug: Lenalidomide;   Drug: Dexamethasone
17 Completed Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Biological: filgrastim;   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Drug: mesna;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: brachytherapy;   Radiation: low-LET cobalt-60 gamma ray therapy;   Radiation: low-LET electron therapy;   Radiation: low-LET photon therapy
18 Completed
Has Results
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide Induction;   Drug: Sequential Maintenance Therapy
19 Active, not recruiting A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera/Rituxan];   Drug: fludarabine;   Drug: cyclophosphamide
20 Recruiting A Study of GDC-0199 (ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Patients With Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: GDC-0199 (ABT-199);   Drug: rituximab [MabThera/Rituxan];   Drug: bendamustine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years